Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment

Abstract The aim of this study was to evaluate the impact of renal impairment on the pharmacokinetics (PKs), safety, and tolerability of daridorexant, a dual orexin receptor antagonist intended for the treatment of insomnia. A single‐center, open‐label study evaluated the PKs of daridorexant in pati...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Benjamin Berger, Clemens Muehlan, Gernot Klein, Jasper Dingemanse
Format: article
Langue:EN
Publié: Wiley 2021
Sujets:
Accès en ligne:https://doaj.org/article/fc8b4cfe396c4a1ebd06e4c57683c6a4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!